Sanofi's deal with Aqemia will accelerate drug discovery through AI, says analyst

In a new move within the pharmaceutical industry, French pharma major Sanofi (Euronext: SAN) has entered into a $140 million deal with Aqemia, a French pharmaceutical technology company.

This collaboration aims to revolutionize drug discovery by leveraging Aqemia's advanced physics algorithms and generative artificial intelligence (AI), says pharma analytics company GlobalData.

Aqemia, built on years of intensive research into physics algorithms, has developed a streamlined technology that integrates physics-based algorithms and generative AI to expedite drug discovery processes. Collaborating with Sanofi, Aqemia will apply its innovative approach to identify and create small molecules with potential across various therapeutic areas.